Lycia Therapeutics

About Lycia Therapeutics

Lycia Therapeutics is a biotechnology company focused on improving patients' lives by stopping disease at its source through extracellular protein degradation. Their mission is to develop therapeutics that target and eliminate dysregulated proteins, initially focusing on autoimmune and inflammatory diseases, with the potential to address a broad range of conditions using their novel LYTAC platform.

Products & Services

LYTAC Platform:A modular therapeutic platform designed to rapidly and selectively reduce levels of disease-causing proteins, including those previously considered undruggable, with potential applications across a broad spectrum of diseases.

Pipeline Programs:Development of therapeutics targeting drivers of autoimmune and inflammatory diseases, leveraging the LYTAC platform to eliminate pathogenic proteins.

Specialties

Extracellular Protein Degradation LYTAC Degraders Autoimmune Diseases Inflammatory Diseases Therapeutics Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 106600000 MR: - FA: 106.6 Million FAN: 106600000	D: 2024-05-13 FD: 2024-05-13	10 investors

Series C Latest

2024-05-13

$106.6M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Carolyn Bertozzi

Professor of Chemistry, Stanford University and Investigator, Howard Hughes Medical Institute and Chair, Lycia Scientific Advisory Board

A

Aetna Wun Trombley

President and CEO

C

Chin Lee

Chief Medical Officer

S

Steve Staben

Chief Scientific Officer

S

Sofia Touami

Chief Business Officer

J

Jian Cao

Vice President, Head of CMC

View 19 more team members with Pro

Unlock Full Team Directory

Recent News